Articles related to Behavioral Health

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Prior ayahuasca experience was associated with lower self-reported depression, stress, and alcohol use among Brazilian ceremony participants, while also correlating with stronger spiritual wellbeing and metaphysical beliefs in an observational study that did not establish causality.

A report examining a celebrity-backed sports prediction campaign highlights concerns about increasing youth exposure to gambling-related marketing. The article connects growing gambling participation among adolescents and young adults with evidence linking gambling disorder to adverse mental health outcomes, including suicidality.

An expert commentary argues that persistent physical symptoms should be approached through a balanced framework that validates patient suffering, excludes dangerous medical illness, and incorporates evidence-informed understanding of brain-body mechanisms without dismissing symptoms as psychological.

Self-reported cannabis use in the United States increased substantially between 2008 and 2022, with particularly pronounced growth in daily or near-daily consumption, while high-frequency alcohol use remained stable or declined during the same period.